( most broadly acting cellular oncogenes...)New binding target for oncogenic viral protein
Navigation Links
New binding target for oncogenic viral protein
most broadly acting cellular oncogenes, and include cyclin E, c-Myc, Notch, and c-Jun," noted Dr. Clurman. "When Fbw7 is mutated in cancers, deregulation of these oncogenic Fbw7 targets is thought to contribute to cancer. SV40 T antigen contains a motif that mimics the destruction signal found in these proteins." However, unlike the other substrates recognized by Fbw7, T antigen is not destroyed by the cell.
Drs. Clurman and Welcker suspect that by acting as a decoy and binding to Fbw7, T antigen protects cellular Fbw7 targets that facilitate viral replication and tumorigenesis.
"I think this work underlines the importance of Fbw7 as an emerging tumor suppressor and the consequences of its loss in tumors," Dr. Welcker emphasized.
"The study of DNA tumors viruses has been an extremely important tool in understanding the cellular pathways that regulate cell division and are disrupted in cancer. Understanding the mechanisms through which these viruses interact with the cellular machinery that regulates cell division may lead to new insights into the pathways that cause cancer. This is an important step to designing new cancer treatment strategies that target these pathways," concluded Dr. Clurman.
'"/>
Source:American Society for Biochemistry and Molecular Biology
Related biology news :
1. Ancient olfaction protein is shared by many bugs, offering new pest control target
2. A bacterial genome reveals new targets to combat infectious disease
3. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
4. Researchers identify target for cancer drugs
5. Study reveals candidate targets for anti-retroviral therapeutics
6. MUHC researchers make cancer target breakthrough
7. Future diabetes drugs may target new protein interaction
8. Smart drug targets deadly brain cancer
9. NHGRI targets 12 more organisms for genome sequencing
10. While on trail of dioxin, scientists pinpoint cancer target of green tea
11. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
Post Your Comments:
Breaking Biology News(10 mins):Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 3While Most Businesses are Laying Off Their Employees The Logo Loft Continues to Hire U S Graphic Designers 61366 1While Most Businesses are Laying Off Their Employees The Logo Loft Continues to Hire U S Graphic Designers 61366 2findNano app puts nanotech in your pocket 14837 1findNano app puts nanotech in your pocket 14837 2High Impact Activity May Be Good for Old Bones 61359 1High Impact Activity May Be Good for Old Bones 61359 2
Other Biology News:Scientists use gene transfer technology and common virus to block neuropathic pain in animals 2Scientists use gene transfer technology and common virus to block neuropathic pain in animals 3Scientists use gene transfer technology and common virus to block neuropathic pain in animals 4Scientists use gene transfer technology and common virus to block neuropathic pain in animals 5Computer modeling reveals hidden conversations within cells 2Computer modeling reveals hidden conversations within cells 3Identical twins may have more differences than meet the eye 2Identical twins may have more differences than meet the eye 3
Breaking Biology Technology:Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 2Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4Reportlinker Adds Pharmacodynamic Assays 2Reportlinker Adds Pharmacodynamic Assays 3Reportlinker Adds Pharmacodynamic Assays 4The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program 2The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program 3
[0] Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas[0] Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit[0] Reportlinker Adds Pharmacodynamic Assays[0] The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program
Other Biology Technology:JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States 2JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States 3Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE 2Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE 3Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMed's Peer-Reviewed Video Journal JoVE 2Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMed's Peer-Reviewed Video Journal JoVE 3
JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United StatesSigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVESigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMed's Peer-Reviewed Video Journal JoVE
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |